Introduction
============

Cervical cancer (CC) is the second leading cause of death from malignancy in women in Mexico and the fourth in the world.[@b1-geg-8-2016-053] Over the years, CC has been studied to define specific characteristics involved in the cancer process to determine the best time for interventions. One of the processes that is currently being studied is the process of DNA methylation and its involvement in cancer treatment. During the cancer process, promoter methylation profiles of tumor suppressor genes are commonly methylated, creating a mechanism for the promotion and development of cancer.[@b2-geg-8-2016-053]--[@b4-geg-8-2016-053] In CC, it is known that the presence of human papilloma virus (HPV) oncoproteins, such as E6 and E7, increases DNA methyltransferase activity and causes global methylation.[@b4-geg-8-2016-053] Nevertheless, other factors may impinge on this process.

Epidemiological and lifestyle factors are implicated in methylation, such as age,[@b5-geg-8-2016-053],[@b6-geg-8-2016-053] obesity,[@b7-geg-8-2016-053] smoking and alcohol intake,[@b8-geg-8-2016-053],[@b9-geg-8-2016-053] physical activity,[@b10-geg-8-2016-053] epigenomic inheritance,[@b11-geg-8-2016-053] and circulating estrogens.[@b12-geg-8-2016-053],[@b13-geg-8-2016-053] However, there are no studies that have evaluated the relationship between lifestyle factors and the methylation processes in CC.

DNA methylation has been useful in identifying the presence of a tumor, as well as determining its status, subtype, and responsiveness to specific therapies such as retinol.[@b14-geg-8-2016-053] In CC, it has been shown that there are epigenetic alterations in genes related to retinol metabolism, such as the retinoic acid receptor (*RAR*) and the cellular retinol-binding protein (*CRBP1*).[@b15-geg-8-2016-053],[@b16-geg-8-2016-053] Nevertheless, it has not been reported whether methylation status can occur in cellular retinoic acid-binding protein-1 (*CRABP1*) and 2 (*CRABP2*) and silence their gene expression.

Retinoic acid (RA) or vitamin A is a metabolite that has an effect on embryonic development, cell growth, differentiation, and apoptosis.[@b17-geg-8-2016-053] These effects are regulated by CRABPs that are related to RA transport within the cell. There are two isoforms, CRABP1 that is expressed in almost all tissues and CRABP2 that is expressed in the skin, nervous system, breast, uterus, and ovary.[@b18-geg-8-2016-053] Both proteins protect amphipathic molecules of RA from oxidative degradations and they also control the availability of retinoids in several metabolic processes. The presence of RA is essential for cell cycle regulation blocking the carcinogenesis process.

Therefore, if methylation in the promoter region of these genes exists, the retinol metabolism could change and affect retinol treatment in CC patients, a commonly used therapy for this cancer. Moreover, knowing other personal factors that promote methylation may allow future interventions for risk populations. The aim of this study is to determine the methylation status of *CRABP* genes and its association with the evolution of the type of squamous intraepithelial lesion (SIL) and CC, as well as the relation with risk factors such as demographic characteristics, habits, and the presence of HPV.

Materials and Methods
=====================

Tissue collection
-----------------

A total of 158 women were selected from the Colposcopy Clinic of Sanitary Jurisdiction II in Ciudad Juarez, Chihuahua, Mexico. Patients were selected by colposcopic and histopathological evaluation, and each patient then signed a consent form for the study. The cervix sample of each patient was obtained by biopsy and by endocervical scraping for the control group. Samples were distributed as low squamous intraepithelial lesion (LSIL; n = 42), high squamous intraepithelial lesion (HSIL; n = 69), and CC (n = 25). Women who showed no intraepithelial lesion (NIL) (n = 22) were selected as control group. All tissue samples were stored in 50 µL of RNAlater^®^ at −20°C (Invitrogen). The ethics committee of Universidad Autónoma de Ciudad Juárez approved this study (CBE.ICB/004.01--14). This research complied with the principles of the Declaration of Helsinki. Patients diagnosed with CC by histopathological evaluation were not on any treatment at that moment. Some demographic characteristics and habit information have been reported to influence the methylation process.[@b6-geg-8-2016-053] Therefore, we collected information about age, family history of cancer, hormonal contraceptive use, smoking, and alcohol intake from patient interviews.

DNA extraction and HPV genotyping method
----------------------------------------

DNA of tissue samples was extracted by the phenol--chloroform--isoamyl alcohol-adapted technique. Before DNA extraction, tissue was treated with 500 µL of lysis buffer (0.2 M Tris--HCL pH 8; 10 mM ethylenediaminetetraacetic acid pH 8; 0.5 M NaCl; 1% sodium dodecyl sulfate) and 2.5 µL of proteinase K (20 mg/mL) and incubated for 30 minutes at 56°C. Then, the phenol--chloroform--isoamyl alcohol technique was used.[@b19-geg-8-2016-053] HPV genotyping was determined by polymerase chain reaction (PCR). PCR conditions and primer sequences used have been reported elsewhere.[@b20-geg-8-2016-053],[@b21-geg-8-2016-053]

Bisulfite treatment and methylation-specific PCR
------------------------------------------------

Extracted DNA was treated with bisulfite using the DNA Methylation-Gold Kit (Zymo Research Corp.) and following the manufacturer protocol. After bisulfite treatment, modified DNA was used as a template for the methylation-specific PCR (MSP) technique. For PCR amplification, 50 ng of bisulfite-modified DNA was added to a final volume of 25 µL PCR mix containing 12.5 µL GoTaq^®^ Green Master Mix (Promega), 1 µL of forward primer, and 1 µL of reverse primer (4 µM for *CRABP1* and 20 µM for *CRABP2*). Primer sequences are shown in [Table 1](#t1-geg-8-2016-053){ref-type="table"}. The unmethylated and methylated regions of *CRABP1* (−193 to +19 bp) and *CRABP2* (−265 to −179 bp) were determined in typical PCR conditions. Annealing temperature for methylated and unmethylated *CRABP1* primers was 60°C. For *CRABP2*, the annealing temperature was 60°C for methylated and 65°C for unmethylated primers. PCR products were loaded on 2.0% agarose gels, stained with ethidium bromide, and visualized under ultraviolet illumination.

Statistical analyses
--------------------

Comparisons for statistical significance were analyzed using SPSS 15.0 software (SPSS Inc.). A two-proportion *z*-test was used to analyze the proportions of methylation status among groups. Association between methylation status and personal characteristics of groups was analyzed using *χ*^2^ or Fisher's exact test, as appropriate. Correlations between the process of cancer (NIL to CC) and the presence of methylation were analyzed with Spearman's correlation coefficient (Rho). All *P*-values represent two-tailed tests and were considered significant at 0.05.

Results
=======

Methylation and hemi-methylation of *CRABPs*
--------------------------------------------

The epigenetic modifications were evaluated in Mexican population distributed in three different groups, according to the grade of SIL or CC. The DNA was modified by bisulfite treatment, and PCR test was performed to determine the methylation status of *CRABP1* and *CRABP2*. The amplification products are shown in [Figure 1](#f1-geg-8-2016-053){ref-type="fig"}. Amplification results show hemimethylation (methylation and unmethylation) patterns in the promoter regions of *CRABP1* and *CRABP2*, compared with the control cell line MCF-7. According to the results, 28.5% (45/158) of the samples showed methylation in the promoter region of *CRABP1*, 7.0% (11/158) in that of *CRABP2*, and only 2.5% (4/158) methylation in both genes at once (as shown in [Table 2](#t2-geg-8-2016-053){ref-type="table"}). Analysis indicated that *CRABP1* methylation is significantly associated with CC (*χ*^2^ = 19.7, *P* \< 0.001) and with increases in the degree of injury (rho = 0.290, *P* \< 0.001). Analysis of proportions showed significant differences between CC and the other groups (NIL, *P* = 0.004; LSIL, *P* \< 0.001; HSIL, *P* = 0.001). In contrast, *CRABP2* methylation was observed to be higher in women with CC but significantly different in women with HSIL (*P* = 0.047). The linear correlation of *CRABP2* methylation and degree of injury showed no statistical significance (rho = 0.145, *P* = 0.069).

Risk factor associated with methylation profiles
------------------------------------------------

Important factors involved in CC and methylation were considered in this study (age, family history of cancer, hormonal contraceptive use, HPV infection, and habits as alcohol and smoke). The statistical multivariate analysis shows in [Table 3](#t3-geg-8-2016-053){ref-type="table"} an association analysis that determines whether the presence of methylation is related to certain personal characteristics. Results of methylation in the promoter of CRABP1, adjusted by diagnosis, were found to be 3.6-fold increased when age was ≥35 years (95% confidence interval \[95% CI\] = 1.58--8.16), 2.2-fold increased with family history of cancer (95% CI = 1.05--4.64), and 2.9-fold increased with the presence of HPV-16 (95% CI = 1.24--6.73). In contrast, methylation of CRABP1 was found to be 0.4-fold decreased in the presence of alcohol consumption (95% CI = 0.18--0.95). The presence of methylation of CRABP2 was not statistically significantly associated with any personal characteristics.

Discussion
==========

Retinoids are commonly used as a chemopreventative and a chemotherapeutic agent for cancer.[@b17-geg-8-2016-053] Nevertheless, the effects of retinoids may be altered by epigenetic changes in CC. Mendoza et al[@b16-geg-8-2016-053] showed that *CRBP1* is methylated in this cancer and that the gene expression is reduced. Additionally, the presence of *RARβ2* methylation increases from low grade to invasive in CC patients.[@b15-geg-8-2016-053] Therefore, metabolism of all retinols has the potential to be changed and generate a resistance to retinoid therapy.[@b22-geg-8-2016-053]

The aim of this study was to determine whether the methylation status was present in *CRABP1* and *CRABP2* gene promoters in CC. First, the proportion of patients with the presence of methylation in *CRABP1* was statistically greater in CC patients than in SIL and NIL patients. This result is similar to that reported in another study.[@b23-geg-8-2016-053] *CRABP2* methylation studies have also described different types and samples of cancer line cells and cancer tissue.[@b24-geg-8-2016-053] In this study, the CC group showed methylation in the promoter region of *CRABP2*, but there was no significant difference when compared with LSIL and NIL. In addition, the proportion of patients with methylation of *CRABP2* was less than that of *CRABP1*. This shows that the process of methylation may be different for the two *CRABPs*. This study analyzed the association of personal characteristic variables that could contribute to methylation in *CRABPs*. The results showed a statistical association between methylation and age, family history of cancer, and HPV-16 genotype infection. Researchers have reported that the presence of global methylation can increase in older people, and this is known as age-related methylation.[@b5-geg-8-2016-053] A family history of cancer may have a genetic influence on methylation,[@b25-geg-8-2016-053] which may contribute to methylation in other chromosome regions, such as the *CRABP1* gene promoter. Nevertheless, this result must be studied in more depth to find a correlation between both variables. On the other hand, it is well known that high-risk HPV oncoproteins, such as E6 and E7, increase DNA methyltransferase activity and cause global methylation. In addition, host cells increase the methylation process by regulating regions of E6 and E7 oncogenes as a defense mechanism, which may also be affecting other regions.[@b26-geg-8-2016-053] Therefore, this study suggests that the methylation pattern of *CRABP1* is changed by personal characteristics and HPV-16 infection. Alcohol consumption has a positive effect on the absence of methylation of *CRABP1*, and studies have reported that it has an influence on methylation development, especially hypomethylation. Alcohol alters DNA transmethylation and homocysteine metabolism by enzymatic inhibition.[@b27-geg-8-2016-053] However, this study suggests that more analysis is needed on the effects of alcohol on the methylation process.

DNA methylation can be used as a marker to diagnose cancer, evaluate prognosis, or predict a therapy response.[@b28-geg-8-2016-053] Considering this, *CRABP1* might be an epigenetic marker. The results of this study determined that the *CRABP1* gene has epigenetic changes that are in response to personal characteristics of the patient. Consequently, this methylation in the *CRABP1* gene promoter may repress gene expression and disturb retinol metabolism. For example, CRABP1 is the protein that regulates cytoplasmic RA concentration and allows the interaction of RA with other proteins.[@b29-geg-8-2016-053] The absence of *CRABP1* gene expression may alter the correct use of RA and be counterproductive in the use of retinoid treatment.

Conclusion
==========

*CRABP1* may be a predictive marker of retinoid therapy response. Nevertheless, we propose to extend this study to determine whether methylation in *CRABP1* and the presence of older age, family history of cancer, HPV-16 infection, and alcohol intake could affect the retinoid treatment in CC. Finally, abnormal methylation processes are of recent interest for many researchers who want to generate epigenetic markers for early detection of cancer or therapeutic prognosis. This study showed that *CRABP1* may be a marker and an important regulator of the retinol pathway in CC.
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![MSP amplification products of representative samples from each group. Patients with CC (16) and HSIL (18) showed hemi-methylation (methylation and unmethylation) patterns in *CRABP1*, and *CRABP2* hemi-methylation was observed in CC (5) and HSIL (3). MCF-7 cell lines were used as methylated (M) positive controls and LINFO (lymphocytes) as unmethylated (U) positive controls.](geg-8-2016-053f1){#f1-geg-8-2016-053}

###### 

Primer sequences for *CRABP1* and *CRABP2*.

                                                                                                                    5′ → 3′                  AMPLICON SIZE (bp)
  ----------------------------------------------------------- --------------------------- ------------------------- ------------------------ --------------------
  *CRABP1*[\*](#tfn1-geg-8-2016-053){ref-type="table-fn"}     Methylated                  Fw                        GGAGGTTTTTTAGTTGGAGAGC   212
  Rv                                                          CTCGCAAAACGAAAACTAACG                                                          
  Unmethylated                                                Fw                          GAGGTTTTTTAGTTGGAGAGTGG   211                      
  Rv                                                          AACTCACAAAACAAAAACTAACACT                                                      
  *CRABP2*[\*\*](#tfn2-geg-8-2016-053){ref-type="table-fn"}   Methylated                  Fw                        CGTTTTCGCGGAGAGCGCG      87
  Rv                                                          AACCGAAATAACCTTCTCCTACGC                                                       
  Unmethylated                                                Fw                          TTTGTTTTTGTGGAGAGTGTGA    86                       
  Rv                                                          TCCAAAATAACCTTCTCCTACACT                                                       

**Notes:**

Primer sequences were designed by Wu et al.[@b23-geg-8-2016-053]

Primer sequences design based on Calmon et al.[@b24-geg-8-2016-053]

**Abbreviations:** Fw, primer forward; Rv, primer reverse.

###### 

Percentage of patients with presence of hemi-methylation in CRABP1 and CRABP2 gene promoters.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
         *CRABP1*\                                                     *CRABP2*\                                                                      
         HEMI-METHYLATION                                              HEMI-METHYLATION                                                               
  ------ ------------------------------------------------------------- ------------------ ----------------------------------------------------------- ---------------
  NIL    18.2 (4/22)[\*](#tfn5-geg-8-2016-053){ref-type="table-fn"}    0.290 (\<0.001)    4.6 (1/22)                                                  0.145 (0.069)

  LSIL   16.7 (7/42)[\*](#tfn5-geg-8-2016-053){ref-type="table-fn"}                       4.8 (2/42)                                                  

  HSIL   26.1 (18/69)[\*](#tfn5-geg-8-2016-053){ref-type="table-fn"}                      4.6 (3/69)[\*](#tfn5-geg-8-2016-053){ref-type="table-fn"}   

  CC     64.0 (16/25)                                                                     20.0 (5/25)                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Statistically significant Spearman's correlation coefficient (rho) (*P* \< 0.05).

Analysis of proportions showing significant differences between CC and the other groups (*P* \< 0.05).

###### 

Association between promoter hemi-methylation of *CRABPs* and personal characteristic variables.

                                                          *CRABP1*, n (%)   *CRABP2*, n (%)                                                                 
  ------------------------------------------------------- ----------------- ----------------- -------------- ----------- ------------ -------------- ------ -------
  Age                                                                                                                                                       
   ≥35 years                                              28 (42.4)         38 (57.6)         3.6            **0.002**   7 (10.6)     59 (89.4)      2.3    0.238
   \<35 years                                             17 (18.5)         75 (81.5)         (1.58--8.16)   4 (4.3)     88 (95.7)    (0.58--9.52)          
  Family history of cancer                                                                                                                                  
   Positive                                               23 (39.7)         35 (60.3)         2.2            **0.032**   3 (5.2)      55 (94.8)      0.5    0.392
   Negative                                               22 (22.0)         78 (78.0)         (1.05--4.64)   8 (8.0)     92 (92.0)    (0.12--2.23)          
  Hormonal contraceptive use                                                                                                                                
   Positive                                               13 (35.1)         24 (64.9)         1.4            0.406       2 (5.4)      35 (94.6)      0.6    0.578
   Negative                                               32 (26.5)         89 (73.5)         (0.61--3.28)   9 (7.4)     112 (92.6)   (0.12--3.18)          
  HPV[§](#tfn7-geg-8-2016-053){ref-type="table-fn"}                                                                                                         
   Positive                                               37 (90.2)         88 (83.8)         1.8            0.434       10 (90.9)    115 (85.2)     1.7    1.000
   Negative                                               4 (9.8)           17 (16.2)         (0.53--7.77)   1 (9.1)     20 (14.8)    (0.22--79.2)          
  HPV 16[§§](#tfn8-geg-8-2016-053){ref-type="table-fn"}                                                                                                     
   Positive                                               22 (44.0)         28 (56.0)         2.9            **0.013**   7 (14.0)     43 (86.0)      3.4    0.081
   Negative                                               15 (20.0)         60 (80.0)         (1.24--6.73)   3 (4.0)     72 (96.0)    (0.79--14.9)          
  Smoke                                                                                                                                                     
   Positive                                               8 (22.9)          27 (77.1)         0.6            0.273       2 (5.7)      33 (94.3)      0.65   0.618
   Negative                                               37 (30.1)         86 (69.9)         (0.21--1.53)   9 (7.3)     114 (92.7)   (0.13--3.37)          
  Alcohol                                                                                                                                                   
   Positive                                               11 (25.0)         50 (81.9)         0.4            **0.035**   2 (3.3)      59 (96.7)      0.3    0.181
   Negative                                               33 (34.4)         63 (65.6)         (0.18--0.95)   9 (9.4)     87 (90.6)    (0.07--1.71)          

**Notes:**

Analysis of odds ratio (OR) is adjusted with diagnostics.

Analysis of 146 patients.

Analysis of positive HPV (n = 125). Bold values show statistical significance (*P* ≤ 0.05).

**Abbreviations:** HM, hemi-methylated; U, unmethylated.
